Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 9/20 | 0.56 |
| ▸ | TMPRSS4 | Q9NRS4 | 13/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MYLK | Q15746 | 1/20 | 0.49 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055785 | 0.76 | TMPRSS4 (0.56) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL13056105 | 0.76 | P2RX1 (0.51) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL13056158 | 0.75 | P2RX1 (0.56) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL13056044 | 0.75 | P2RX1 (0.56) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL2790218 | 0.72 | P2RX1 (0.68) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL13055676 | 0.72 | P2RX1 (0.55) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL13056108 | 0.71 | P2RX1 (0.41) | P2RX1P2RX4P2RX7MEN1KMT2A | |
| SCHEMBL13056107 | 0.71 | ALDH1A1 (0.43) | MEN1KMT2A | |
| SCHEMBL15889794 | 0.70 | LMNA (0.69) | KMT2A | |
| SCHEMBL18343975 | 0.68 | TMPRSS4 (0.57) | P2RX1TMPRSS4P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47786-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES L.C. (US) | 2019-12-31 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-RE46724-E1 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES, L.C. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846727-B2 | Haloalkyl heteroaryl benzamide compounds | ROMARK LABORATORIES, L.C. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292274-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | P2RX1 3855/4885TMPRSS4 1983/4885P2RX4 3268/4885 |
| US-20140341850-A1 | HALOALKYL HETEROARYL BENZAMIDE COMPOUNDS | HDHD5, HAVCR2, AADAC | P2RX1 3855/4885TMPRSS4 1983/4885P2RX4 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.